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Children with autism spectrum disorders (ASD), characterized by a range of behavioral
abnormalities and social deficits, display high incidence of gastrointestinal (GI)
co-morbidities including chronic constipation and diarrhea. Research is now increasingly
able to characterize the “fragile gut” in these children and understand the role that
impairment of specific GI functions plays in the GI symptoms associated with ASD.
This mechanistic understanding is extending to the interactions between diet and
ASD, including food structure and protein digestive capacity in exacerbating autistic
symptoms. Children with ASD and gut co-morbidities exhibit low digestive enzyme
activity, impaired gut barrier integrity and the presence of antibodies specific for
dietary proteins in the peripheral circulation. These findings support the hypothesis
that entry of dietary peptides from the gut lumen into the vasculature are associated
with an aberrant immune response. Furthermore, a subset of children with ASD exhibit
high concentrations of metabolites originating from microbial activity on proteinaceous
substrates. Taken together, the combination of specific protein intakes poor digestion,
gut barrier integrity, microbiota composition and function all on a background of ASD
represents a phenotypic pattern. A potential consequence of this pattern of conditions
is that the fragile gut of some children with ASD is at risk for GI symptoms that may be
amenable to improvement with specific dietary changes. There is growing evidence that
shows an association between gut dysfunction and dysbiosis and ASD symptoms. It is
therefore urgent to perform more experimental and clinical research on the “fragile gut” in
children with ASD in order to move toward advancements in clinical practice. Identifying
those factors that are of clinical value will provide an evidence-based path to individual
management and targeted solutions; from real time sensing to the design of diets with
personalized protein source/processing, all to improve GI function in children with ASD.
Keywords: microbiota, gastrointestinal, dietary protein, gut-brain, fragile gut, probiotics, constipation, diarrhea
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INTRODUCTION
Autism spectrum disorder (ASD) is characterized by varying
degrees of neural dysfunction that lead to behavioral
abnormalities including: stereotyped/repetitive behaviors,
impairments in social interaction, lack of verbal and nonverbal
language skills, insistence on routines and intense or
idiosyncratic interests (1–3). ASD includes a heterogeneous
range of disorders with various levels of intellectual functioning,
verbal abilities, and multiple genetic etiologies. The estimated
prevalence of autism in 8-year-olds in 2012 was 1:68 children
with a much higher occurrence in boys (23.6 per 1,000) than
in girls (5.3 per 1,000) (4). Over the past decade, the incidence
rate has been steadily increasing (5). While increased awareness,
concern and diagnostic criteria of ASD has expanded, some
postulate that this increased prevalence cannot be entirely
attributed to increased recognition and more expansive
diagnostic criteria (5). There are currently no biomarkers
for ASD and diagnosis is made solely on the history and
observation of behavioral abnormalities using the Autism
Diagnostic Interview - Revised (ADI-R) assessment (6) and
the Autism Diagnostic Observational Schedule (ADOS) (7).
Treatment of ASD symptoms focus on augmenting the obvious
behavioral abnormalities with pharmacologic, cognitive, social,
and communication therapies.
There is active research into the mechanisms that cause
different autism phenotypes, including studies of genetic
markers, structural, and functional brain abnormalities,
immune dysfunction, gut microbial dysbiosis, sensitivity to
environmental toxin exposure, and oxidative stress (8–13).
However, gastrointestinal dysfunction is common in children
with ASD (14) yet overlooked as unrelated to the disease
process, or viewed as a disorder that simply co-occurs with
the autistic symptoms. There is a strong correlation between
the presence of gastrointestinal symptoms and autism severity
(15) as ASD patients with gastrointestinal symptoms display
higher measures of irritability, anxiety and social withdrawal
(16). Gut dysfunction in children with ASD deserves further
investigation, especially given the potential for intervention. Gut
function is now recognized as highly variable, even within the
normal population; many disease processes occurring at distant
body sites have been found to have origins in gut, microbial
composition and metabolism (17).
The concept of the “fragile gut” is proposed to be involved in
a subset of children with ASD and that impaired gastrointestinal
(GI) function, including deficiency in protein digestive capacity,
is central to the GI symptoms associated with ASD and may
exacerbate behavioral symptoms in ASD.
Gastrointestinal and Immune Dysfunction
in Children With ASD
Gastrointestinal co-morbidities are common in children with
ASD and have been reported to affect 9–91% of patients (18–
21) with the prevalence of symptoms four times greater than
in children without ASD (14). This unusually broad range is
due to the variability in symptoms included in diagnosis as
well as the limited number of studies assessing the prevalence
of gastrointestinal symptoms. In addition, these symptoms
are often underreported because many of these children are
nonverbal or have difficulty with communication, and many
parents have difficulty recognizing gastrointestinal symptoms in
their children. Even so, the most commonly reported symptoms
include chronic constipation, diarrhea, and abdominal pain (14,
20, 21). Food allergies are also more common in children with
ASD than age-matched controls (22) and may also be under-
diagnosed due to the similar reasons (2). Certain foods appear
to trigger both gastrointestinal and behavioral symptoms in
children with ASD (18). To date, the poor reactions to particular
foods experienced by these children has not been explicitly
linked with differences in gut microbiota, immune function and
digestive capacity in children with ASD relative to typically
developing children.
Morphologically, there is evidence to suggest that
gastrointestinal structure is altered in children with ASD.
Examination of distal ileal biopsies from children with ASD
reveals crypt cell proliferation, thickening of the basolateral
membrane (23) of the gut epithelium and increased intestinal
permeability (24, 25). These observations all suggest chronic
immune activation in the gut and epithelial damage. One study
found abnormally high intestinal permeability in nearly 40%
of autistic patients and in 21% of their first-degree relatives
whereas this excessive permeability was present in <5% of
normal control subjects (24, 25). Increased permeability would
contribute to heightened reactions to food components in the
intestinal tract of children with ASD. Interestingly, individuals
with ASD on specific protein-restricted diets (wheat and
dairy free) have significantly lower intestinal permeability
than those on unrestricted diets (25). Children with ASD and
gastrointestinal symptoms experience unique gastrointestinal
immunopathology characterized by ileal nodular lymphoid
hyperplasia (26), high levels of mucosal pro-inflammatory
lymphocyte infiltration with inversely low levels of regulatory
lymphocyte populations (27), and colonic lesions containing
high numbers of infiltrating γδ and CD8+ T cells with associated
epithelial damage (23). Unlike inflammatory bowel diseases,
there is lack of clear TH1 or TH2 skewing in ASD with the
observation that IL-4, IL-2, and interferon gamma (IFN-γ)
are elevated in the duodenal mucosa while IL-4 is elevated
in the colon (27). Immune-mediated epithelial damage to the
gut lining via serum IgG and complement C1q co-localization
at the basolateral membrane (28) suggests that autoimmune
mechanisms may play a role. Autoimmunity may arise out of
increased immune responses to dietary proteins and potential
cross reactivity to proteins in the gut or brain, which will be
discussed in more detail in the following sections. Interestingly,
children on specific protein-restricted diets show lower levels
of activated colonic intraepithelial lymphocytes and underlying
lamina propria lymphocytes (CD3+TNFα+) compared to
children on unrestricted diets (27).
Immune abnormalities in ASD are not restricted to the
gut and systemic immune imbalance is common. Changes in
numbers and activation of macrophages, T cells, B cells, and
natural killer cells have all been observed in patients with
ASD (29, 30). While some studies have observed a shift from
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TH1 to TH2 cell type with decreased production of IL-2 and
IFN-γ and increased production of IL-4 (31), others state that
there is no clear cytokine polarization profile, and attempting
to categorize the disease based on the traditional TH1/TH2
dichotomy may oversimplify and incorrectly characterize the
immune dysfunction in children with ASD (32). Interestingly,
in vitro stimulation of peripheral blood mononuclear cells from
children with ASD with certain dietary proteins (including
β-lactoglobulin and α-lactalbumin from cow’s milk and gliadin
from wheat but not casein cow milk protein or soy protein)
resulted in elevated pro-inflammatory cytokine production when
compared to healthy controls as well as non-ASD controls
with non-allergic food hypersensitivity (33, 34). Together, these
observations suggest that overall gut immune function is altered
and food antigens may provide a pro-inflammatory stimulus in
children with ASD and gastrointestinal symptoms. However, it
has been unclear whether these manifestations simply co-occur
with the disorder, are a result of the abnormal neural functions
that characterize the disorder, or are contributing to the etiology
of the disease state.
Characterization of the “Fragile Gut”
Abnormal gastrointestinal functions in children with ASD
include diminished digestive capacity. It is generally assumed
that well-nourished, healthy children and adults who lack a
history of gastrointestinal symptoms (e.g., chronic diarrhea,
constipation, gastric reflux) or pancreatic insufficiency have
little or no undigested or unabsorbed nutrients in the feces.
The gastrointestinal tract digests and absorbs nutrients from
consumed food matrices while excluding harmful bacteria and
toxins. Pancreatic enzymes are produced in amounts that exceed
substrate requirements allowing for complete digestion. Brush
border enzymes and transporters have expression levels and
activities capable of ensuring total absorption of nutrients in
the small intestine (35). However, these normally successful
processes may be disturbed in children with ASD and
gastrointestinal symptoms.
The gut is the largest immune organ and the main site of
immune system development (36). Considering that the gut
immune system constantly encounters foreign material, immune
imbalance can cause a lack of tolerance to dietary components
and commensal microbes (37). The gastrointestinal tract is the
second largest site of neurological tissue in the human body
playing roles from nutrient sensing to appetite regulation (38).
For the purposes of this review a “healthy gut” is one that is
able to (1) effectively extract and absorb nutrients from complex
food matrices; (2) properly identify foreign materials as benign
(e.g., common food substances) or harmful (e.g., pathogenic
bacteria); (3) support the colonization of the gut by commensal
organisms while eliminating pathogens; (4) restrict uptake or
passage of potentially damaging substances out of the gut lumen
through maintenance of gut barrier integrity; and (5) provide
appropriate nutrient and energy status signals to other organ
systems (35). All of these “healthy gut” functions are vital, and
therefore, dysfunction of any one of these processes can cause or
exacerbate disease throughout the body.
In this review, we will define the term “fragile gut” as a
gastrointestinal tract that is basically “healthy” (i.e., lack of
defined gastrointestinal disease), but is not robust to stressors,
challenges, ormicrobial insults. Stressors include diets containing
indigestible or toxic components or infectious agents. The
concept is that a fragile gut influences a variety of clinical
and non-clinical situations where gut dysfunction is not the
explicit disease state or site, but rather a secondary problem.
Examples of populations with a fragile gut include premature
infants, the elderly, patients undergoing chemotherapy and
children with ASD and gastrointestinal symptoms. The fragile
gut phenotype in children with ASD includes a distribution
of dysbiotic and pathological states. While a subset has been
diagnosed as exhibiting explicit immunopathologies, others
are asymptomic normally, but become symptomatic when
confronted with challenges from poorly digested diets. Transient
blooms of detrimental bacteria (e.g., proteobacteria) and “pulses”
of microbial metabolites have been observed, as discussed below
(Tables 1, 2). The causes of fragile gut remain incompletely
understood. We hypothesize that the fragile gut’s etiology
results from a range of factors including digestive capacity, the
digestibility of food ingredients consumed, genetic susceptibility
as it affects gastrointestinal regulatory modulation, immune
tolerance development, and gut microbial composition.
We propose that the fragile gut is influenced by dietary
protein digestion. Incomplete digestion increases microbial
protein fermentation (putrefaction) and inflammatory
putrefactive metabolites, which can result in decreased gut
barrier integrity, increased gut-associated immune responses,
and microbial population shifts. In some children with ASD,
reduced proteolytic capacity and colonic putrefaction may
cause gastrointestinal problems and also exacerbate ASD
symptoms (Figure 1). Identification of a fragile gut phenotype
in ASD has both diagnostic and therapeutic applications.
Identification of susceptibility and characterization of exogenous
triggers has diagnostic implications. Therapeutic implications
include avoidance of specific triggers and enhancement of the
“robustness” of the intestinal microbiota, immune system, and
intestinal tissues.
It is important to note that most of the available evidence
linking gut dysfunction and dysbiosis to ASD is at this point
based on associations and not causal relationships. Therefore, we
are calling for future experimental and clinical studies designed
to specifically address the potential causal relationship between
these factors, including the gold standard of dietary intervention
trials in children with ASD and GI symptoms.
EVIDENCE FOR PROTEIN MALDIGESTION
IN CHILDREN WITH ASD
Low Digestive Enzyme Activity
Protein digestive capacity may be impaired in some children
with ASD, which would contribute to the abnormal immune
activation and gastrointestinal symptoms observed in these
populations (Figure 1). However, there are no studies directly
assessing the level and activity of proteolytic digestive enzymes
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TABLE 1 | Overview of studies exploring the gut microbiota in children with ASDs.
Comparison Sample site Method Level Type Change References
ASD+GI vs.
TD
Stool (n = 13 and
8)
Gastric/SI (n = 7
and 4)
16S rRNA
sequencing
Phylum, genus,
species
Clostridia (g)
Ruminococcus (g)
Bacteroidetes (p)
Clostridium difficile (s)
Non-sporeforming anaerobes/microaerophiles
↑
↑
↑
↑
↑
(39)
ASD (n = 15)
vs. TD (n = 8)
Stool 16S rRNA
primers
RT-PCR
Genus, species Clostridium bolteae (s)
Cluster I (∼g)
Cluster XI (∼g)
↑
↑
↑
(40)
ASD (n = 58)
vs. SIB (n =
12) vs. TD (n
= 10)
Stool FISH – 16s RNA
probes
Genus, species Clostridium histolyticum (s) ↑ (41)
ASD + GI (n
= 33) vs. SIB
(n = 7) vs. TD
(n = 8)
Stool 454 Titanium
pyrosequencing
(culture-ind)
Phylum, genus,
species
Firmicutes (p)
Actinobacteria (p)
Bacteroidetes (p)
Proteobacteria (p)
Bifidobacterium angulatum (s)
Bifidobacterium longum (s)
Bifidobacterium (g)
Bacteroides (g)
Clostridium (g)
Desulfovibrio (g)
Ruminococcus (g)
Desulfovibrio piger (s), D. desulfuricans (s), D. intestinalis
(s)
Bacteroides vulgates (s)
Overall diversity and richness
↓
↓
↑
↑
↓
↓
↓
↑
↑
↑
↓
↑
↑
↑
(42)
ASD (n = 58)
vs. TD (n =
39)
Stool Culture? Genus, species Bifidobacterium (g)
Enterococcus (g)
Lactobacillus (g)
Bacillus (g)
Klebsiella oxytoca (s)
↓
↓
↑
↑
(15)
ASD (n = 23)
vs. SIB (n =
22) vs. TD (n
= 9)
Stool 16S rRNA
primers
RT-PCR
Genus, species Bifidobacteria spp (vs. CON and SIB)
Akkermansia muciniphila (vs. CON)
Bacteroides fragilis (ASD: +GI vs. –GI)
↓
↓
↑
(21)
ASD + GI (n
= 15) vs. TD
+ GI (n = 7)
Ileal and cecal
biopsies
16S rRNA
primers
RT-PCR
All levels Bacteroidetes (p)
Firm/Bact (p)
Clost/Bact (o)
Firm+Prot (p)
Clostridiales (o)
Lachnospiraceae&Ruminococcus(f)
Proteobacteria (p)
Betaproteobacteria (c)
↓
↑
↑
↑
↑
↑
↑
(43)
ASD vs. TD (n
= 20)
454 Titanium
pyrosequencing
Phylum, genus Proteobacteria (p)
Verrucomicrobia (p)
Akkermansia (g)
Prevotella (g)
Veillonellaceae (f)
Overall diversity
↓
↓
↑
↓
↓
↓
(44)
ASD vs. PDD
vs. TD (n =
10)
Stool 16S rDNA and
rRNA primers
RT-PCR
All levels Overall diversity
Firmicutes (rRNA and rDNA) (p)
Bacteroidetes (p)
Fusobacteria and Verrucomicrobia (p)
Differential rRNA clustering (not rDNA)
Ruminococcaceae (f)
Faecalibacterium/Ruminococcus (g)
Clostridiaceae (f)
Lachnospiraceae (f)
Prevotella and Alistipes (g)
Sutterellaceae (f)
Parasutterella (g)
Enterobacteriaceae (f)
Proteus and Shigella (g)
Bifidobacteria (g)
Akkermansia muciniphila (s)
↑
↓
↑
↓
↓
↑
↑
↑
↑
↑
↓
↑
(45)
ASD, autism spectrum disorder; TD, typically developing; +GI, with GI symptoms; –GI, without GI symptoms; SIB, sibling of ASD; PDD, pervasive developmental disorder; p, phylum;
c, class; o, order; f, family; g, genus; s, species.
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TABLE 2 | Overview of studies exploring gut putrefactive metabolites in children with ASDs.
Comparison Sample site Metabolites Change Microbiota assoc/other
comments
References
Infants (n = 28),
children (n = 60),
and ASD (n = 262)
Urine HPHPA
3-(3-hydroxyphenyl)-3-hydroxy- propionic acid
(Phe metabolite)
↑↑ Clostridia spp (some) hyp
Psychosis and level ↓ w antibiotic
treatment in schizophrenia
(46)
ASD (n = 59) vs. TD
(n = 59)
Urine p-cresol
Only age <7 and corr with autism severity
↑ Clostridium difficile (s) hyp
Expresses p-hydroxyphenylacetate
decarboxylase
(47)
Case report Blood/urine Propionic acid
Ammonia
↑
↑
Associated with pancreatitis (48)
ASD (n = 23) vs. TD
(n = 31, 22 SIB)
Stool Ammonia
Phenol
Acetate, butyrate, propionate
Isobutyrate, valerate, isovalerate
p-cresol
↑
↑
↑
↑
—
Similar dietary intakes (49)
ASD vs. PDD vs. TD
(n = 10)
Stool Free amino acids (FAA)
Ammonia
Phenol
p-cresol
Propionic acid
Indole/3-methylindole
Total med and short chain fatty acids
↑
↑
↑
↑
↑
↑
↓
↑ Bacteroides (g) corr
↑ Bacteroides (g) corr
↑ Clostridia (g) hyp
↑ Clostridia (g) hyp
↑ Bacteroides (g) corr
↑ Clostridia (g) corr
↓ Ruminococcoceae (f) hyp
(45)
ASD (n = 33) vs. TD
(n = 33)
Urine Total p-cresol and derivatives
p-cresylsulfate
p-cresylglucuronate
Free p-cresol
↑
↑
↑
—
Exclusive to age <8 for all (50)
ASD, autism spectrum disorder; TD, typically developing; SIB; sibling of ASD; corr, correlation found; hyp, hypothesis only.
in these children. One study found that the activity of several
saccharolytic digestive enzymes is low in children with ASD and
gastrointestinal symptoms (51). Characterization of the upper
gastrointestinal tract in these children revealed decreased activity
of one or more disaccharidases or glucoamylase in 58.3% of
children with ASD compared to healthy controls. Remarkably,
nearly half of these children showed decreased activity in two or
more of these enzymes and all children with low enzyme activity
had loose stools and/or gaseousness. Stimulation of pancreatic
output with secretin administration showed that children with
ASD on average had a higher pancreatico-biliary fluid output
compared to healthy controls (51). While secretin treatment
is now a disproven therapy (52), the authors hypothesized
that the hypersecretory response to intravenous secretin might
be due to the absence of regular secretin stimulation of
the pancreas. However, this response could also be due to
chronic pancreatic insufficiency as increased pancreatico-biliary
output has been observed in patients with exocrine pancreatic
insufficiency (53). While this study found no evidence of
pancreatic insufficiency in children with ASD, they did observe
hypertrophy and hyperplasia of the upper gastrointestinal
Paneth’s cells (specialized immune cells interdigitated between
enterocytes of the intestinal epithelium). The authors noted that
Paneth cell hypertrophy/hyperplasia has also been reported in
hamsters after ligation of the pancreatic duct (54) and in patients
with chronic pancreatitis (55).
Later studies investigated brush border enzyme function
in children with ASD further. One study found significantly
decreased levels of ileal sucrose isomaltase, maltase glucoamylase,
and lactase mRNA in children with ASD and gastrointestinal
symptoms when compared to typically developing children
who also had similar gastrointestinal symptoms (43); therefore,
these findings are autism-specific and not generalized to all
gastrointestinal dysfunction. Indeed, 93.3% of children with
autism in this study had a deficiency in at least one of these
enzymes, while 80% had deficiencies in at least two, and 73.3%
had deficiencies in all three (with deficiency defined as levels
<25% of controls). These digestive enzymes are located on
the brush border of the enterocyte membrane, and thus their
levels and activity could be decreased by chronic inflammation
of the gastrointestinal tract or other disturbances in enterocyte
maturation and migration. If this is the case, then other brush
border enzymes, such as peptidases, are impaired as well.
Altered Levels of Systemic Amino Acids
and Peptides
Children with ASD who have shown elevated levels of
urinary peptides of dietary origin (56) provide further evidence
that this population experiences impaired protein digestion
coupled with increased intestinal permeability. Unfortunately,
the interpretation of these findings must be viewed with some
caution as they have arisen out of the “opioid excess theory.” This
theory of ASD’s origin hypothesizes that breakdown products
of certain dietary proteins (mainly casein and gluten) are
potent agonists of opioid receptors that can exert systemic
effects and are able to cross the blood brain barrier (56).
Indeed, many of the urinary peptides detected from children
with ASD can be classified as exorphins (exogenous opioids)
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and include casomorphins, gliadinomorphins, gluteomorphins,
deltorphin and dermorphin. Treatment of these subjects with
an extended gluten-free, casein-free (GFCF) diet (2–4 years)
resulted in significant reduction in urinary peptide levels as well
as improvement in behavioral metrics (57–59), despite abundant
intake of meat and fish protein (58). Suggestively, several animal
studies have shown that inhibition of gut peptidases, specifically
dipeptidyl peptidase IV (DPP-IV), results in increased levels of
urinary peptides of dietary origin (60, 61). While the “opioid
excess theory” is not widely accepted and supporting evidence
is limited, these findings support the hypothesis that a subset of
children with ASD experience reduced digestive enzyme activity,
and undigested dietary peptides can cross the intestinal mucosal
barrier and exert biological effects systemically.
Plasma amino acid profiles tend to be altered in children
with ASD, although studies have reported mixed results. While
some studies have shown elevated levels of certain plasma amino
acids, such as glutamic acid, aspartic acid (62, 63) and taurine
(62), others have shown decreased levels of certain amino acids,
especially glutamine (62–64). Arnold et al. (65) found that
children with ASD on both restricted (GFCF) and unrestricted
diets had frequent essential amino acid deficiencies. Compared
to controls, children with autism on unrestricted diets were
more likely to be deficient in valine, leucine, phenylalanine, and
lysine, while children on restricted diets were additionally more
likely to be deficient in isoleucine (65). Adams et al. found
decreased levels of isoleucine, phenylalanine, tryptophan, and
taurine; they hypothesize that this is due to decreased protein
intake or impaired protein digestion. They postulated that the
latter hypothesis is more likely because most essential amino
acid levels were normal (66). Low levels of certain plasma
amino acids in children with ASD suggest both an impaired
capacity for protein digestion as well as increased passage of
dietary peptides into systemic circulation by way of compromised
intestinal integrity. Finally, certain plasma amino acids either
serve as neurotransmitters (e.g., glutamate) or serve as precursors
(e.g., tryptophan and tyrosine) for important neurotransmitters
(e.g., serotonin and dopamine). Perturbations in these systems
are common in children with autism and contribute significantly
to autistic symptoms (67–69).
Autoantibodies Against Dietary Peptides
and Gut Peptidases
Low proteolytic enzyme activity in the gut would lead to
increased levels of undigested peptides in the gut lumen, resulting
in increased plasma and urinary concentrations of these peptides.
High levels of foreign peptides in the systemic circulation can
induce an adaptive immune response that leads to autoantibody
(i.e., self-reactive antibody) production (Figure 1). Therefore,
the subsequent cross-reaction of the resulting antibodies with
neural tissue proteins may play a role in the etiology of autistic
symptoms.
Multiple studies have found elevated levels of circulating
antibodies against several microbial products including
Chlamydia pneumoniae peptide Streptococcus M protein (70),
streptokinase (SK) (71), and heat shock protein (HSP-60) (72) in
children with ASD compared to healthy controls. Elevated levels
of antibodies against dietary proteins have also been detected
in children with autism including IgG, IgM and IgA against
butyrophilin milk protein (70), casein (57, 71, 73–75), gliadin
(57, 71, 72, 74, 75), IgG against deamidated α-gliadin (75),
and IgA against lactalbumin, β-lactoglobulin and ovalbumin
(73).
Bacterial proteins and peptides have been reported to show
sequence homology and subsequently induce antibody cross-
reactivity with certain human brain tissue proteins (74). Immune
reactions mounted against dietary peptides may subsequently
damage neural tissue in children with ASD that cause or
exacerbate behavioral symptoms. Elevated levels of antibodies
were found against myelin basic protein and neurofilament
proteins in 58-70% of children with ASD (76, 77) with studies
corroborating these findings and discovering elevated levels
of antibodies against a number of other neuronal proteins
including myelin-associated glycoprotein, ganglioside, myelin
oligodendrocyte glycoprotein (70), and cerebellar peptides
(74). In vitro studies have also demonstrated that antibodies
against proteins of gut origin are able to cross-react with
neuronal proteins and peptides (74). One study showed
that antibodies against the gliadin peptide cross-reacted with
cerebellar peptide with 17% binding (74). Antibodies against
crude (undigested) gliadin showed 23% binding to cerebellar
peptide, milk protein showed 56%, egg protein showed 68%
binding, while corn or soy protein showed little to no cross-
reactivity. Additionally, significant increases in anti-cerebellar
peptide antibodies were concomitant with increases in anti-
gliadin antibodies in most ASD sera, thus supporting the
hypothesis of an autoimmune etiology. Furthermore, studies
of the maternal origins of autoantibodies in ASD found
that fetal brain protein reactive immunoglobulins can be
isolated from approximately 12% of mothers who have
children with ASD (78). Subsequent studies using a non-
human primate model showed that the administration of
these autoantibodies to rhesus monkeys during pregnancy
resulted in offspring with abnormal social behavior and enlarged
brain volume compared to controls (79). This group has
since defined an autism subset, termed maternal autoantibody-
related (MAR) autism, defined by the maternal presence of
clinically significant ASD-specific antibody biomarkers (80).
Children found to fall into the MAR-autism subset experience
elevated stereotypical behaviors (80) and more extreme brain
enlargement (81) compared to children with other types of
autism.
Autoimmune cross-reactivity has also been shown to affect
several gastrointestinal proteins in addition to neural proteins.
Vojdani et al. hypothesized that antibodies against antigens
from infectious agents may react with lymphocyte receptors
(71, 74). Two of these lymphocyte receptors, DPP-IV and
aminopeptidase N (CD13), are also located on the brush border
of the small intestine and are involved in degradation of
small peptides as part of the protein digestive process. They
found that ASD sera contained significantly greater levels of
antibodies against both of these gut peptidases compared to
healthy children. In addition, the vast majority of children with
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FIGURE 1 | Robust vs. Fragile Gut Function in Children with ASD. (A) Robust Gut: the healthy gut displays robust digestion of proteins and simple sugars by the small
intestine brush border enzymes that make these nutrients absorbable. After digestion, very few intact nutrients remain and indigestible polysaccharides (fiber) remain.
This fiber is consumed by saccharolytic bacteria, which line most of the large intestine, and produce beneficial byproducts (such as short chain fatty acids).
Undigested proteins or amino acids are consumed by putrefactive bacteria, which are few in number, and produce potentially harmful putrefactive metabolites that are
easily detoxified. The blood and lymphatics in the villi do not directly interact with the lumen of the small intestine, preventing the interaction of antigenic food
molecules with the underlying immune tissue. (B) Fragile Gut: the fragile gut of children with autism displays reduced digestive capacity. The inflammation and
deterioration of the gut lining may cause reduced expression and activity of brush border disaccharidases and peptidases and greater amounts of intact simple sugars
and proteinaceous substrates and less fermentable fiber. This proteinaceous substrate is consumed by the more prevalent putrefactive bacteria producing greater
amounts of putrefactive metabolites, such as ammonia, phenols, and sulfides. The blood and lymphatics in the villi are in contact with the lumen due to the excessive
inflammation and the undigested proteins in the intestine are able to directly pass. This process allows for interaction of antigenic proteins with immune tissue leading
to an aberrant immune response and subsequent autoantibody production.
ASD who had elevated levels of these anti-peptidase antibodies
also had elevated levels of antibodies against gliadin, casein,
SK, or HSP-60 and many had elevated levels of all of these
antibodies (71, 72). In vitro studies found that binding of anti-
DPP-IV antibodies to DPP-IV significantly reduced its activity
(p < 0.05) (72). These findings suggest that children with
ASD have elevated levels of antibodies against gut peptidases
that may impair their function and lead to increased levels
of peptides in the gut. This would increase the likelihood
that dietary peptides enter systemic circulation and set off an
autoimmune reaction that leads to neuronal protein targeting in
the brain.
Intestinal Microbial Dysbiosis
Some of the microbial perturbations reported in ASD (Table 1)
support the hypothesis of impaired protein digestion in
this cohort. Impaired protein digestion would not only
result in increased levels of peptides entering the systemic
circulation, but also entering the distal gastrointestinal tract.
This increased level of proteinaceous substrate could modulate
the composition of the microbiota and lead to dysbiosis,
an imbalance between protective and detrimental taxa in
the gut (Figure 1). While studies on protein fermentation
(putrefaction) in the human colon are extremely limited,
several studies indicate that increased levels of protein in
the colon leads to increased levels of protein-metabolizing
(putrefactive) bacteria (82, 83), reduced levels of fiber-fermenting
(saccharolytic) bacteria (83–85), and reduced bacterial diversity
(85) as well as increased levels of putrefactive metabolites in
the colon (83, 85–88). These metabolites have been associated
with inflammatory bowel diseases such as ulcerative colitis
(89, 90). The effects of these metabolites on host physiology
have been studied using mainly in vitro models and have
been shown to increase intestinal permeability (87, 91–93)
and reduce overall health of colonocytes (87, 91, 94–96).
Therefore, the prevalence of gastrointestinal symptoms may
be directly related to an altered gut microbiota in these
children.
Table 1 lists the studies examining the fecal microbiome
of children with ASD. Children with ASD appear to have
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more bacterial diversity (42, 45) and possess lower overall
abundance of potentially beneficial taxa, such as Bifidobacteria
and Akkermansia, even among healthy siblings relative to
unrelated control children (15, 21, 42), though some populations
appear to differ from this trend (42, 44). Further, reports
typically show that children with ASD have higher counts of
clostridia than controls (39–43), though this is not universally
true (44). Interestingly, certain species of clostridia are very
adept at metabolizing protein and amino acids (97–99).
Studies examining bacterial enrichment in batch incubations
of human fecal slurries supplemented with peptides and
amino acids have found an outgrowth of certain species of
clostridia (97, 99). The majority of the proteolytic activity
in the large intestine is attributed to bacterial taxa including
Bacteroides, Clostridium, Propionibacterium, Fusobacterium,
Streptococcus, and Lactobacillus (98). Both Bacteroides (21, 42)
and Lactobacillus (15) have been found at higher levels in
children with ASD. In addition, rats fed a high protein diet
have been shown to have increased levels of Bacteroides spp.
and certain Proteobacteria, including escherichia/shigella, as
well as decreased levels of akkermansia and bifidobacteria spp.
relative to rats on normal protein diet (83). Proteobacteria
have also been shown to be increased in children with ASD
(42, 43). These results suggest that proteolytic bacterial taxa
are enriched in children with ASD as a consequence of high
levels of undigested protein entering the colon. However,
studies in this area are limited, and data on the effects
of high protein diets on the colonic microbiota in humans
are scarce. In addition, the activities of these gut bacteria
remain to be determined and future studies will be needed
to define the metabolic activities (e.g., metagenomics and
metatranscriptomics) of the gut microbiota rather than purely
microbial composition.
From a symptomatic perspective, gastrointestinal complaints
were significantly associated with Clostridia in patients with
ASD when compared with healthy unrelated controls (41).
In addition to differences in Bifidobacterium spp., Wang et
al., also found the abundance of Akkermansia muciniphila
(A. muciniphilia) to be decreased in ASD, and again intermediate
in siblings, as well as elevated relative numbers of “B. fragilis”
in children with ASD and gastrointestinal symptoms vs.
children with ASD without gastrointestinal symptoms. It was
hypothesized that lower levels of A. muciniphila indicate a
thinner gastrointestinal mucus barrier, since this species is
mucolytic and may be reduced due to lack of substrate
(21). Williams et al. (43) compared the bacterial adherent
to the intestinal mucoepithelium (from biopsies) in children
with ASD and gastrointestinal co-morbidities to children with
gastrointestinal issues but without ASD. Comorbid conditions
were also similar between groups with the most commonly
reported conditions being atopic manifestations (asthma, atopic
dermatitis, and allergic rhinitis). Bacteroidetes and Firmicutes
were the most prevalent taxa in ileal and cecal biopsies of both
autistic and control children. However, there was a significant
increase in Firmicutes/Bacteroidetes ratios in autistic ileal and
cecal samples, which has been interpreted to reflect a general
state of dysbiosis in other conditions, such as obesity (100).
Overall, these studies support the hypothesis that abnormal
microbial composition of the gastrointestinal tract can cause or
exacerbate GI symptoms associated with ASD. Other studies
suggest that this abnormal microbiota may even be associated
with the symptoms and severity of ASD (15). While dietary
components are the primary determinants of gut microbial
composition after birth in mammals, the cause of the dysbiosis
observed in ASD has not been thoroughly studied in the
context of diet, protein maldigestion, or gut abnormalities.
However, the combined effects of immune imbalance with
digestive dysfunction and intake of dietary proteins with low
digestibility may all play a role in promoting gastrointestinal
symptoms andmicrobial dysbiosis in this susceptible population.
Furthermore, these dysbiotic bacteria may directly cause or
exacerbate gastrointestinal symptoms due to their potential to
produce damaging metabolic byproducts.
High Levels of Fecal Putrefactive
Metabolites
A variety of enteric bacteria, including clostridia, desulfovibrio,
and Bacteroidetes are enriched in batch cultures high in
proteinaceous substrates (97–99) and in children with ASD
(39, 42). These bacteria can ferment dietary proteins in a
process called putrefaction (98, 101). Byproducts of microbial
putrefaction can be detrimental to gut health (102). Microbial
metabolites produced from the saccharolytic fermentation of
dietary fiber (e.g., vitamins and short chain fatty acids) are
generally recognized as being beneficial to human health.
In contrast, the products of putrefaction [e.g., ammonia,
phenols, indoles, sulfides and biogenic amines (101)] have been
associated with reduced viability of colonic epithelial cells in
vitro (103), increased intestinal permeability (92, 93), DNA
damage (104) and the inhibition of cellular respiration in
colonocytes (95, 105, 106). Increased colonic protein, due to
reduced digestive capacity, serves as a food source for these
putrefactive colonic microbes. Thus, a diminished capacity to
digest dietary protein in the small intestine and/or consumption
of proteins resistant to digestion can lead to elevated colonic
protein and peptide levels, and thus increased concentrations of
these detrimental protein-derived metabolites. The heightened
level of putrefactive metabolites found in children with ASD
(Table 2) (47, 49, 63, 107, 108) suggests that protein maldigestion
in the small intestine plays a role in driving not only
gastrointestinal symptoms, but also neural symptoms of this
disorder.
One specific consequence of protein fermentation is the
ability of certain gut bacterial species to catabolize threonine
and alanine to produce propionic acid, a metabolite that also
increases with increased protein in the diet (101). Propionic acid
concentrations are higher in children with ASD than healthy
children (49). In addition, acute and chronic abnormalities of
brain function are well-documented in propionic acidemia, a
common form of organic aciduria resulting from an inborn error
of metabolism that causes propionyl-CoA carboxylase deficiency
(109, 110). One case study reported the occurrence of autism
in a 7-year old girl with propionic acidemia (48). While it is
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possible that these disorders co-occurred by coincidence, the
authors postulate that the propionic acidemia contributed to
the emergence of ASD symptoms. MacFabe and colleagues have
thus eloquently hypothesized that proprionic acid plays a role in
the etiology of ASD (107) and have subsequently developed an
animal model of ASD using proprionic acid to induce autistic-
like symptoms (111). Rats treated intracerebroventricularly with
propionic acid displayed numerous behavioral and physiological
traits characteristic of human ASD including hyperactivity,
repetitive and abnormal motor movements, seizures, increased
brain oxidative stress markers (lipid peroxidation products and
protein carbonylates), decreased glutathione and glutathione
peroxidase activity, and increased neuro-inflammation indicated
by increased reactive astrogliosis and activated microglia.
Subsequent studies showed that propionic acid-treated rats
display social behavior impairments (112, 113), altered brain
lipid profiles (114), restricted behavioral interests and cognitive
impairment (115), hypophagia and taste avoidance (116),
DNA damage (117), as well as sexual dimorphism in regard
to acoustic startle response and prepulse inhibition (118),
all of which are implicated in human ASD. In addition,
another group has shown that clindamycin-induced clostridia
overgrowth causes propionic acid elevation and subsequent
genotoxicity in the brain of hamsters (119), which supports
the hypothesis of the gut origin of this metabolite. Propionic
acid also affects colonic smooth muscle contraction, mast
cell activation, serotonin release, and gastric motility (120);
these factors could provide a direct connection between
microbial metabolic activity and gastrointestinal symptom
occurrence.
Propionic acid is capable of reacting with ammonia,
another putrefactive product, to produce β-alanine (121).
β-alanine is structurally similar to γ-aminobutyric acid (GABA),
an inhibitory neurotransmitter. β-alanine has been found
to be higher in children with ASD compared to controls
(63), can function as a partial GABA antagonist (122) and
can cross the blood brain barrier (123), making it another
potential candidate for ASD symptom induction (121).
Urea cycle disorders, characterized by hyperammonemia,
can also present with confusion, bizarre behaviors, and
autistic-like symptoms (124, 125). Finally, several other
putrefactive metabolites have also been found to be elevated
in the urine and feces of ASD patients including p-cresol
(47, 108), p-cresylsulfate, p-cresylglucuronate (108) and
ammonia (49). P-cresol and p-cresylsulfate levels were also
positively associated with stereotypic and compulsive/repetitive
behaviors in these children (108), as well as overall severity
of autistic symptoms (47). Elevated levels of putrefactive
metabolites have also been found in animal models of
ASD including 3-(3-hydroxyphenyl)-3-hydroxypropionic
acid, 4-hydroxyhippuric acid, 4-hydroxybenzoic acid
(126) and 4-ethylphenylsulfate (127). Abnormally high
concentrations of putrefactive metabolites in children with
ASD compared to controls could not be explained by
dietary intake as consumption of protein, sugar, starch, and
fiber was similar between groups (49). These differences
may be better explained by digestive capacity, the gut
microbiota, and overproduction of putrefactive metabolites
in children with ASD, compared to typically developing
children.
FACTORS AFFECTING PROTEIN
DIGESTIBILITY
Inherent Properties of Proteins
Dietary proteins display a wide range of susceptibility to digestive
processes in the human gut depending on sequence, structure
and the food matrix in which it is present: certain proteins
(e.g., human β-casein) are easily hydrolyzed into amino acids in
the small intestine, whereas others (e.g., wheat storage proteins
like gliadin and gluten) are highly resistant to proteolysis (128).
Protein digestibility depends on several factors, including size,
charge, amino acid sequence, tertiary structure (129–131) and
post-translational modifications such as glycosylation (132, 133)
and phosphorylation (134). In general, even under idealized
conditions, proteins from animal sources tend to be more
susceptible to enzymatic hydrolysis and demonstrate apparent
digestibility over 95% with milk proteins having the highest
apparent digestibility at around 98%. Plant proteins have lower
apparent digestibility with values ranging from 70 to 85%.
However, certain animal structural proteins, such as collagen,
elastin, and keratin contain unusual secondary structures that
are resistant to proteolysis (128). For example, the collagen triple
helix is characterized by stabilizing crosslinks between peptide
chains that are difficult to cleave and reduce digestibility. The low
digestibility of plant proteins is partially due to similar structural
features as well as relative insolubility, compact structures of
intracellular protein bodies and high structural integrity of the
plant cell wall and seed coat (128). Therefore, vegetable proteins,
particularly those found in legumes and cereal grains, require
cooking in addition to other processing methods to partially
improve digestibility.
Beyond protein structure, dietary protein digestibility can
be reduced by anti-nutritional factors that reduce protein
bioavailability. These factors include protease inhibitors, tannins
and phytates (128) that are commonly found in plant foods
(135, 136). Trypsin inhibitors are found in many legumes
(common bean, cow pea, lima bean, peanut, garden peas and
soy beans) and cereal grains (wheat and barley) as well as
potatoes and some squash. These inhibitors bind trypsin, and
sometimes chymotrypsin, within the gut lumen to impair protein
digestion (128). In addition, many of these anti-proteases are
resistant to digestion and are also highly stable to thermal and
acid denaturation and so can retain at least partial activity
even with cooking (137, 138). Tannins are naturally occurring
plant polyphenols that function to bind and precipitate proteins
(139, 140) and are found at high levels in legumes, nuts and
other minority cereals such as sorghum and barley as well
as many types of fruits (136). However, fruit is not a major
source of protein in the diet. Tannins have also been shown
to reduce feed digestibility by directly inhibit enzymes in the
intestines of ruminants (139) and through formation of tannin-
nutrient complexes (141, 142). Overall, high levels of tannins
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in livestock feed diminish weight gains, apparent digestibility
and feed utilization efficiency, partially through their action in
inhibiting protein digestion (143). Finally, phytates are mineral-
binding molecules found in the kernels of cereal grains including
wheat, maize, rice, barley, sorghum, oats, rye, and millet (135)
that may also decrease protein digestibility (144).
Protein Processing Effects
The processing of commodities into foods has important effects
on the digestibility of proteins. Both protein structure and
anti-nutritional factors can be altered by food processing heat
treatments (128, 145). Heat treatment can either increase or
decrease protein digestibility depending on the type of protein,
and the temperature and duration of treatment (128). For
example, cooking increases digestibility of legume proteins,
but the increase in temperature negatively affects enzymatic
hydrolysis and solubility of sorghum (146, 147) and milk
proteins, and negatively affects maize proteins (146, 147). In
targeted applications, the effects, of protein thermolyzation on
digestibility, have been explored extensively, for example in
the context of milk proteins in infant formula, which often
undergo extreme heat treatment (148). Interestingly, several
studies have shown that extensive heat treatment of milk
proteins (e.g., spray drying, in-can sterilization) results in various
protein modifications (e.g., increased protein-lipid and protein-
protein interactions, increased denaturation, and formation
of modified side chains) that reduces their digestibility both
in vitro (149–153) and in vivo (153, 154). Heat treatment
of bovine milk to an extent similar to that used in the
industrial sterilization and processing of yogurt, makes the casein
protein more resistant to digestive processes; this resistance is
hypothesized to be due to heat-induced aggregate formation
(152). In addition, reaction of the amine functional group
on free amino acids with a reducing sugar results in the
formation of Maillard reaction products that can also inhibit
proteolysis (153). The amino acid lysine is more susceptible to
this reaction that other amino acids due to the presence of its
ε-amine group. When lysine reacts with the milk sugar lactose,
lactosyllysine forms and inhibits the activity of trypsin (153).
Other Maillard reaction products were similarly been found
to inhibit protein digestion. Furthermore, irradiation, alkaline
processing, oxidation, high pressure processing, extrusion and
freeze-thaw cycling of foods can also affect protein digestibility
(128, 145). In addition to the other deleterious properties of
ultra-processed foods [e.g., the presence of harmful additives,
preservatives, colorants and other toxins (155)] the negative
effects of certain processing techniques on dietary protein
digestibility prompt consideration of the exclusion of specific
foods and the inclusion of protein sources based on their
digestibility by at risk individuals (e.g., minimally processed
dairy, eggs, meat, and fish) in the diets of children with
ASD.
Intestinal Environment
Beyond the effects of protein structure and processing on
digestibility, the individual’s digestive environment alters degree
of protein digestion. Specifically, individuals vary in their
digestive capacity based on the level and activity of luminal
proteases and brush border peptidases, gastric and intestinal
luminal pH, and microbial proteolytic activity (145). For
example, in chronic malnutrition, pancreatic proteases are
depleted (156). Pancreatic insufficiency, as determined by
reduced fecal elastase-1 levels (<200µg/g stool), is also common
in gastrointestinal disorders such as celiac disease in children
(157) and adults (158) that is correlated with the presence of
villous atrophy (159) but not nutritional status (160). Other
intestinal disorders are also associated with a high incidence
of pancreatic insufficiency including irritable bowel syndrome
(161), Crohn’s disease, ulcerative colitis (162), giardiasis- or cow
milk-related enteropathy (163), and diarrhea of infancy (164).
Newborn infants are at particularly high risk for pancreatic
insufficiency. One study found that 43% of newborn term infants
have low elastase-1 levels that reach adult levels by 48 hours of
life while preterm infants experience elastase-1 levels <30µg/g
that do not reach adult levels until 14 days of life (165). Studies
have also found reduced chymotrypsin levels in the stool of
prematurely born infants who are small for gestational age
compared to prematurely born infants who are appropriately
sized for their gestational age (166). Pancreatic insufficiency
can also be induced by enteric pathogen colonization leading
to acute enteritis in adults (167). In addition, low elastase-1
activity has also been found in diabetics (168) and the elderly
(169). Pancreatic insufficiency has also been closely associated
with increased markers of gastrointestinal inflammation (170), a
common occurrence in children with ASD.
Impaired pancreatic function can be reversed, except for
cases of severe and extensive malnutrition in which refeeding
does not recover function (171, 172), other cases of pancreatic
insufficiency are potentially reversible (163, 169). In the case
of celiac disease, the reduced pancreatic exocrine function
returns to normal after at least 12 months on a gluten-free
diet (163). In addition, the symptoms of pancreatic insufficiency
can be improved with enzyme supplementation (169). These
observations suggest that it is possible to ameliorate digestive
deficiency through enzyme supplementation as well as through
implementation of personalized diets for individuals with
reduced digestive capacity. For the fragile gut of children with
ASD, this means a nutrient-rich diet containing appropriate
protein sources.
The ability to routinely diagnose digestive issues is limited.
The gold standard for assessment of pancreatic insufficiency
(elastase-1 levels below 200µg/g) is an indirect measure of
pancreatic exocrine function (173). One study (174) compared
the fecal elastase-1 test with a direct assessment of pancreatic
function, the pancreatic function test (PFT) (174). Results
demonstrated that the correlation between the pancreatic
function test and elastase-1 results were poor. The elastase-
1 test has a sensitivity of only 41.7%, a specificity of 49.2%
and a positive predictive value of only 14% (174). Thus, the
incidence of pancreatic insufficiency is underestimated and the
development of more sensitive indirect assessment tools is
warranted. Furthermore, exocrine pancreatic function is only one
dimension of protein digestive capacity and impairments in other
aspects of this process are beginning to be explored (145).
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LINKS BETWEEN GUT HEALTH AND
BEHAVIOR
It is now recognized that there is a connection between the
health of the gut and the presence of psychiatric symptoms.
For example, irritable bowel syndrome is associated with a high
prevalence of depression, panic disorder, generalized anxiety
and post-traumatic stress disorder (175). Explorations into
the sources of these co-morbidities have led to hypotheses
concerning the composition and activity of the gut microbiota
and their interaction with the host immune system (176). There
are several mechanisms by which the intestinal microbiota
modulate the function of the central nervous system to
influence mood and behavior including: augmentation of
gut barrier integrity with subsequent changes in systemic
levels of bacterial components and metabolites; synthesis of
neuropeptides and other neurotransmitters; modification of
local and systemic inflammation; moderation of absorbed
nutrients, such as decreasing absorption of beneficial and
essential nutrients (e.g., vitamins, short chain fatty acids,
essential fatty acids, essential amino acids) while concomitantly
increasing synthesis of detrimental compounds (e.g., putrefactive
metabolites mentioned earlier); modulation of brain-derived
neurotrophic factor; and regulation of microbial proliferation by
increasing small bacterial overgrowth and/or gastric/intestinal
pathogens (12). Thus, the composition and activity of the gut
microbiota during critical periods of development has a profound
influence on both the development of immune function and
the development of the central nervous system in children
with ASD as well. However, causation cannot be implied
based on this observation. Treatment of children with ASD
with oral vancomycin (an antibiotic not readily absorbed by
the gastrointestinal tract and thus limited in its effect to the
gut lumen) has a short-term benefit for some symptoms of
autism in some individuals (177), which is expected if certain
microbial pathogens are contributing to behavioral symptoms.
Therefore, the presence of gut microbial dysbiosis during critical
periods of development has an impact on both immune and
neurodevelopment. Early dietary considerations must be taken
into account to promote the proper development of these
systems.
EFFICACY OF RESTRICTED DIETS
Given the general detrimental effect that consumption of
proteins with low digestibility could have in children with ASD,
examination of studies that consider diets where several of these
proteins are eliminated can provide insight into the hypothesis
of impaired protein digestive capacity in this cohort even
when specific mechanisms of action have not been determined.
Several observational and clinical studies looking at the effect of
specific protein-free diets, such as GFCF, have reported mixed
results in regard to benefit in reduction of gastrointestinal
symptoms and behavioral problems (178). Multiple studies have
reported significant beneficial effects of the GFCF diet including
normalization of urinary peptide levels (179), reduced intestinal
permeability (25), and overall improvement of behavioral metrics
(179–183). ASD children with gastrointestinal disturbances have
been found to show greater improvement in ASD behaviors
(e.g., self-stimulatory behaviors, hyperactivity, sensory seeking
behaviors, temper tantrums, lining up objects, and echolalia),
physiological symptoms (e.g., bodily rash, red ring around
anus, constipation, diarrhea and seizures), and social behaviors
(e.g., social responsiveness, eye contact, engagement, attention
span, requesting behavior, naming objects, pointing, language
production, and imaginative play) on the GFCF diet compared to
children with ASD but without overt gastrointestinal symptoms
(183).
There are important limitations to all dietary intervention
studies conducted in this field, such as short duration of
treatment (<1 year), heterogeneous sampling (did not select for
patients with gastrointestinal symptoms), lack of reporting of
changes in gastrointestinal symptoms, and lack of testing for
compliance, which is important considering that these proteins
are ubiquitous in the modern diet. Indeed, strict implementation
of the diet has resulted in substantially greater improvement
ASD behaviors, physiological symptoms, and social behaviors
(183). In addition, there are likely other dietary proteins that
are similarly difficult to digest that have not been considered
and need to be minimized in cases of a fragile gut. Overall,
dietary intervention studies in these children have not been able
to address the multiple, integrated consequences of inappropriate
proteins in the diets of individuals with ASD, including
dietary protein digestion, gut-associated immune responses, and
potential perturbations to the intestinal microbiota, much less
provide the diagnostics to build tailored solutions. The future
of research in this area will require investigation of whole food
components, as gluten-free/casein-free diets are actually wheat-
free/dairy-free, and thus food needs to be the focus rather than
isolated dietary components.
FACTORS AFFECTING FOOD CHOICE
AFFECT PROTEIN CONSUMPTION IN
CHILDREN WITH AUTISM
Children with ASD are notoriously “picky eaters”; they have
particularly strong food aversions and can be ultrasensitive
to food context, especially texture (184–186). Specifically, this
cohort has a high oral sensitivity level (184, 187), which means
that the children will choose, crave, and avoid certain food smells,
tastes, temperatures, and textures (184). For example, it has been
observed that children with ASD are less likely to be able to
identify sour or bitter tastes and have a decreased olfactory sense
compared to typically developing children (188).
Along with an oral sensitivity, children with ASD have lower
facial feedback when performing pleasurable tasks that induce
laughter or other positive reactions normally seen in typically
developing children (189). This decreased facial feedback could
have an impact on the way that these children consume foods.
One research study proposed that texture preference is based on
the sensation received from mouth movements, such as whether
the food is chewed, crunched, smushed, or sucked (190).
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Sensorial properties of foods are important, especially in
children with ASD, since proteins affect food texture and are
not homogenous in the diet. Different food commodities provide
various types of proteins with varying configurations, including
differences in amino acid composition as well as secondary and
tertiary structure. Some dietary proteins are easily broken down
completely into their constitutive amino acids during digestion in
the small intestine, whereas others are more resistant to digestion
(128). These proteins can survive intact or partially intact to the
colon where they serve as a food source for putrefactive bacteria
(191). However, consumers typically select and ingest proteins
not on the basis of digestibility, but rather on their sensorial
properties.
Palatability varies and is dependent upon food processing
methods that alter protein texture and structure. For instance,
there are many industrial meat processing techniques that change
the texture and the palatability of the meat such as, the use of a
pulsed electric field that perturbs cellular architecture (192), the
preparation of meat batter at high temperatures that denatures
myosin and myofibrillar proteins (193), and the adjustment of
pH that alters meat tenderization properties (194). Additionally,
dairy product treatments affect palatability by changing the
structures of proteins and lipids. For example, sonication
of dairy products disrupts protein composition (195), and
homogenization and heat treatment cause increased protein-lipid
interaction and disruption of milk fat globule structure (153).
Therefore, processing of meat and dairy products could alter
chemical structures in these foods and may reduce palatability
for groups particularly sensitive to food texture, such as children
with ASD.
The necessity to implement personalized diets based on an
assessment of individual responses to different protein sources in
this population is crucial given this populations’ tendency toward
food aversions, preferences and dietary needs. Occasionally,
children with ASD consume inadequate amounts of protein.
While there is limited research on differences in protein intake
in affected children, one study found that 42.1% of autistic
children consume inadequate amounts of proteins (defined as
<77% of the daily recommended intake) (186). While other
studies have shown no differences in intake level (196), some
have shown decreased protein consumption in ASD children
compared to other family members (197). In addition, protein-
containing foods were least preferred by the children with
ASD as 67.4 ±18.7% of the children studied were reported to
“never consume” them. Comparatively, foods high in starches
were most preferred as only 44.2 ± 22% of the children with
ASD never consumed them (186). However, these studies are
extremely limited and protein source/processing has not been
considered. In another study, children with autism were reported
to consume significantly fewer foods in dairy (p = 0.001) and
protein (p = 0.001) categories than typically developing children
(198). In addition, there was no difference in the number of foods
consumed from each food category by families which suggests it
was not the family’s eating habits having the effect (198). In view
of this review’s hypothesis, if children have an immune reaction
to certain dietary proteins, they would develop aversions to foods
high in protein. Neural pathways from the brain may be altered
in response to the immune activation from indigestible proteins
in the fragile gut (199). If indigestible proteins are a contributing
cause of inflammation, then a personalized diet that avoids
specific proteins would be beneficial. Future advancements in
the development of personalized diets will need to look for
diagnostic tools capable of determining the effects of specific
protein consumption in this cohort. To ensure compliance, the
organoleptic and sensorial properties of foods and the taste
preferences of the ASD individual into account. Well-annotated
databases of nutritional requirements and taste preferences need
to be integrated in order to design personalized diets.
POTENTIAL TREATMENT OPTIONS
Probiotic Supplementation
Probiotics, as defined by theWHO in 2001 (200), are “live micro-
organisms which, when administered in adequate amounts,
confer a health benefit on the host.” They are often, but
not always, lactic-acid producing bacteria, such as lactobacilli,
lactococci, and bifidobacteria, or yeasts such as “saccharomyces
boulardii” (201). While probiotic therapy has been suggested
in multiple reviews as a potential treatment for children with
ASD and gastrointestinal symptoms (1), there have been no
randomized controlled trials of this type of intervention in
this cohort to date. Even so, it has been reported that as of
2009, one-fifth of physicians encourages use of probiotics for
children with ASD (202). One study showed that Lactobacillus
acidophilus administration (5 × 109 CFU/day, twice a day for 2
months) significantly reduced a marker of invasive pathogenic
candidiasis in children with ASD and gastrointestinal symptoms
(203). However, half of the children in the study were on
restricted diets and the study design lacked a control group.
A separate observational study demonstrated reduced levels of
myeloperoxidase, a marker of inflammation and oxidation, in
children with ASD and gastrointestinal symptoms who were
undergoing probiotic therapy compared to similar children
not taking probiotics (204). Probiotic supplementation has
been used in animal models of autism with efficacy. Hsiao
et al. (127) demonstrated gastrointestinal barrier defects and
microbiota abnormalities in a maternal immune activation
(MIA) mouse model of ASD. Oral treatment for offspring with
MIA with the human probiotic “Bacteroides fragilis” (“B. fragilis”)
not only increased gut barrier integrity and reversed some
microbial alterations, but also ameliorated certain behavioral
deficits. Defects in communicative, stereotypic, anxiety-like
and sensorimotor behaviors were significantly improved with
probiotic administration. Therefore, further investigation into
the role of probiotic supplementation in children with ASD
and gastrointestinal symptoms via properly designed randomized
controlled trials that correlate behavioral and physiological
outcomes is warranted.
Digestible Proteins
A treatment option for children with ASD and gastrointestinal
symptoms is to replace indigestible proteins in the diet with
more digestible sources. While GFCF, diets (which are actually
wheat-free/dairy-free) have shown some efficacy in reducing
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ASD associated gastrointestinal co-morbidities, as previously
mentioned, the effect is often marginal with some studies
showing greater benefit than others (25, 178–183). Ambiguity
in outcomes may in part be due to the simple fact that
these dietary protein sources are replaced by alternative protein
sources that are also indigestible, such as maize, legumes
and other plant-based proteins. In addition, these gluten-
free options also tend to be high in refined carbohydrates
and also promote bacterial dysbiosis in the fragile ASD gut.
In order to increase the efficacy of the GFCF diet, protein
sources need to be replaced by highly digestible protein. Many
researchers and clinicians hesitate to recommend restricted
diets for children with ASD due to dietary imbalances, sensory
preferences and low protein intakes that may result from this
recommendation (205). However, a properly designed diet that
includes digestible protein sources, as well as recommended
amounts of vitamins and minerals, can be implemented to
improve gastrointestinal function and nutritional status in
children with ASD. Combination treatments that utilize high
quality protein diets and appropriate complex carbohydrate
intake, would promote beneficial bacterial colonization, increase
saccharolytic fermentation, reduce microbial putrefaction and
subsequently normalize gut inflammation and permeability.
This improved gut function could result in reduced ASD
symptoms that are a consequence of circulating putrefactive
and inflammatory bacterial metabolites as well as diet-derived
autoantibodies on nervous system function in children with ASD
and gastrointestinal co-morbidities.
Digestive Enzymes
If digestive capacity is impaired in a subset of children
with ASD, another potential treatment option is digestive
enzyme supplementation, specifically with a full panel of
proteases. A limited number of studies have been conducted
to test the efficacy of digestive enzyme supplementation on
gastrointestinal and behavioral outcomes in children with ASD.
One study (206) utilized a unique combination of proteases
called ENZYMAID that included alpha-fetoprotein (AFP),
bromelain, CASE-GLUTINASE, and phytase (206). AFP is
acid-stable and breaks up large proteins into peptides in the
stomach, bromelain is a combination of proteolytic enzymes
found in pineapple, CASE-GLUTINASE contains both exo- and
endopeptidases and has DPP-IV activity, and phytase acts to
break down phytate (a plant mineral-binding protein) in order
to increase mineral bioavailability. Significant improvement
in all parameters measured was observed including eye
contact, attention, mood, anxiety/compulsion, comprehension,
digestion, and sleep. The most significant improvements were
observed in socialization (90% improved) and hyperactivity
(80% improved) (206). A more recent study corroborated these
findings using Neo-Digestion oral solution containing papain
and pepsin (207). Results found significant improvements in
emotional response, general autistic impression scores, general
behavior and gastrointestinal symptoms including stool quality,
abdominal pain, vomiting and food variety. The main behavioral
improvements included less restricted and repetitive behavior
as well as stereotypic behavior. No correlation was observed
between behavior improvement and gastrointestinal symptom
improvement, suggesting that behaviors did not improve simply
due to lessening of gastrointestinal symptoms (207). While
another study found no benefit of enzyme supplementation, this
study did not control for probiotic use, which was noted for some
subjects (208). Previous studies have shown that some probiotic
products contain bacterial strains with potent DPP-IV activity
(206), which could confound the results.
SUMMARY AND CONCLUSIONS
In conclusion, impaired gut immune and digestive function, high
levels of circulating dietary peptides, presence of autoantibodies
that cross react with dietary proteins, increased levels of
putrefactive metabolites with potent actions on gut and behavior,
and the microbial patterns associated with ASD, such as high
prevalence of clostridial species and high ratios of Firmicutes
to Bacteroidetes, suggest that protein-driven microbial dysbiosis
exacerbates both gastrointestinal and ASD symptoms. In general,
saccharolytic microbes that thrive off of dietary glycans (such
as fermentable fibers) tend to produce short chain fatty acids,
lower the pH of the intestine, lower pathogens and promote the
maturation and metabolism of gut epithelial cells. In contrast,
proteolytic microbes that thrive off of incompletely digested
dietary proteins produce byproducts such as ammonia, amines,
phenols, and sulfides that have a negative effect on gut health
(102) and brain function (120). Therefore, the consumption
of dietary proteins that are difficult to digest by the reduced
digestive capacity of the fragile ASD intestine results in elevated
levels of peptides in the gut. These aberrant peptides have
the potential to negatively affect gut barrier integrity, feed
proteolytic bacteria that produce harmful byproducts, and set
off an aberrant immune response, either directly or through
the promotion of bacterial dysbiosis. Microbial dysbiosis can
promote further improper activation of the immune system
leading to a vicious cycle of dysbiosis, inflammation and
further damage to gastrointestinal tissue and function. The
working hypothesis is that children with ASD experience reduced
proteolytic capacity that leads to colonic putrefaction that
causes gastrointestinal problems that exacerbate ASD symptoms
(Figure 1). Therefore, characterizing the digestive capacity of
children with ASD is a personalization strategy capable of guiding
diets to include appropriate source and processing methods
for dietary proteins. This style of personal intervention will
allow for the design and implementation of individualized diets,
with particular consideration of protein source and processing,
to improve gastrointestinal function and promote a beneficial
microbial composition in children with ASD.
Understanding the gut etiology of disease has been hindered
by technological and clinical limitations that have inhibited
advancements in the field of dietary protein digestion. The
application of peptidomics will allow for characterization of
protein digestion site, specifically within the gastrointestinal
tract. Currently, protein digestion is viewed as a single event
definable in very narrow terms when, in fact, digestion is
a very broad process varying in multiple aspects of space
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and time. Recent technological advancements in the area
of proteomics and peptidomics now provide the capabilities
to perform extensive characterization of digestive processes
occurring continually along the length of the small intestine
(209–212). Likewise, the technologies to map protein digestion
in the gut—peptidomics—is only recently emerging (211,
213). The development of innovations for sampling the
human gut, the progression of improvements in peptidomics,
and the application of biomarkers for protein digestion
(including metabolomics, microbial sequencing and multiplexed
inflammatory protein monitoring), will enhance understanding
in this field. Specifically, these innovations will improve
knowledge of dietary proteins’ digestive processes in specific
sections of the gut in various populations. Intestinal protein
digestion can affect regulatory processes, immune development,
and microbial colonization, especially during the perinatal
period, and in other susceptible populations where inadequate
digestion is particularly harmful.
Further research in this area should expand on the
current body of literature that has focused on determining
associations between gut function and ASD symptoms to include
experimental and clinical studies designed to determine causal
relationships between these factors. These studies will have broad
implications to many diseases associated with gastrointestinal
function, and knowledge gained will play a crucial role in the
design of personalized diets with protein sources tailored to
individuals with a fragile gut.
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